Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 23 Apr 2023
The treatment of chronic thromboembolic pulmonary hypertension with balloon pulmonary angioplasty has an evolving safety profile over the years, from 2013 to 2022, as revealed by an analysis of more than two dozen studies.
Read Full NewsFor patients with locally advanced esophageal cancer, front-loading immunotherapy with induction chemo and chemoradiotherapy, without maintenance immunotherapy, may improve outcomes.
Posttreatment ctDNA positivity correlates with worse relapse-free survival and earlier recurrence in patients with locally advanced cervical cancer, real-world data show.
There’s now a hint that GLP-1 receptor agonists might prevent hysterectomies in endometrial intraepithelial neoplasia/early-stage endometrial cancer, but prospective trials are needed to confirm it.
1.
recognizing the mechanism by which the replication of the host cell is outperformed by the skin cancer virus.
2.
High numbers of rural patients cross state lines for cancer care
3.
Watch for Psoriasis After Cancer Immunotherapy, Study Says
4.
It has been discovered that personalized dosing in the treatment of prostate cancer improves patient outcomes.
5.
Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal
1.
Understanding SVR Normal Range: A Guide to Achieving Optimal Health
2.
Driving Impact: Oncology Pharmaceutical Marketing Strategies in the USA
3.
Digital Oncology: How Remote Monitoring and Mobile Health Are Transforming Cancer Care
4.
Understanding Verrucous Carcinoma: Symptoms, Diagnosis, and Treatment Options
5.
An Overview Of Daunorubicin: What Is It Used For And How Does It Work?
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V
2.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II
4.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
5.
A New Era in Managing Cancer-Associated Thrombosis
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge